Ionizable cationic lipids
The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
1. A compound selected from the group consisting of AKG-UO-1, AKG-UO-1A, AKG-UO-1B, AKG-UO-2, AKG-UO-4, AKG-UO-4A, AKG-UO-5, AKG-UO-6, AKG-UO-7, AKG-UO-8, AKG-UO-9, AKG-UO-10, Compound 17, Compound 18, Compound 19, Compound 23, Compound 24, and Compound 25:
2. The compound of claim 1 , wherein the compound is selected from the group consisting of AKG-UO-1, AKG-UO-2, AKG-UO-4, AKG-UO-5, Compound 17, Compound 18, Compound 19, Compound 23, Compound 24, and Compound 25:
3. The compound of claim 1 , wherein the compound is AKG-UO-1:
4. The compound of claim 1 , wherein the compound is AKG-UO-2:
5. The compound of claim 1 , wherein the compound is AKG-UO-4:
6. The compound of claim 1 , wherein the compound is AKG-UO-5:
7. The compound of claim 1 , wherein the compound is Compound 17:
8. The compound of claim 1 , wherein the compound is Compound 18:
9. The compound of claim 1 , wherein the compound is Compound 19:
10. The compound of claim 1 , wherein the compound is Compound 23:
11. The compound of claim 1 , wherein the compound is Compound 24:
12. The compound of claim 1 , wherein the compound is Compound 25:
13. The compound of claim 1 , wherein the compound is AKG-UO-1A:
14. The compound of claim 1 , wherein the compound is AKG-UO-1B:
15. The compound of claim 1 , wherein the compound is AKG-UO-4A:
16. The compound of claim 1 , wherein the compound is AKG-UO-6:
17. The compound of claim 1 , wherein the compound is AKG-UO-7:
18. The compound of claim 1 , wherein the compound is AKG-UO-8:
19. The compound of claim 1 , wherein the compound is AKG-UO-9:
20. The compound of claim 1 , wherein the compound is AKG-UO-10: